Hydroxycarbamide — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

7 Recruiting

8 Completed trials

15 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 5 Phase II/III: 1 Phase II: 5 Phase I/II: 2 Phase IV: 2

Oversight events:

5 temporary halts 4 urgent safety measures across 5 trials

View oversight register →

Indications tested

Primary myelofibrosis 2 Polycythaemia vera 2 Meningioma 1 Sickle cell disease 1 Myelofibrosis 1

Sponsors using this IMP

Akershus University Hospital 1 Celgene Corp. 1 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Helse Bergen HF 1 Italfarmaco S.p.A. 1 Karolinska University Hospital 1 Kartos Therapeutics Inc. 1 Les Hopitaux Universitaires De Strasbourg 1 Merck Sharp & Dohme LLC 1 Novartis Pharma AG 1 Novo Nordisk A/S 1 Oslo University Hospital HF 1

All trials

15 total

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Dis… Recruiting

2024-513750-30-00 Phase II 1 country Theravia
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Phase III 1 country The University Of Birmingham
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting

2023-505232-36-00 Phase III 9 countries Merck Sharp & Dohme LLC
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto… Recruiting

2022-501992-15-00 Phase I/II 1 country Helse Bergen HF
Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting

2022-502276-23-00 Phase III 11 countries Italfarmaco S.p.A.
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended

2024-515953-52-00 Phase III 8 countries Sobi Inc.
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea… Ended

2023-509019-97-00 Phase I/II 1 country Karolinska University Hospital
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Phase II/III 13 countries Kartos Therapeutics Inc.
Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up Ended

2024-515562-14-00 Phase IV 1 country Les Hopitaux Universitaires De Strasbourg
HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet… Ended

2022-502338-20-00 Phase IV 1 country Novartis Pharma GmbH
Research study investigating how well NDec works in people with sickle cell disease Ended

2023-508506-22-00 Phase II 4 countries Novo Nordisk A/S
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Phase III 10 countries Celgene Corp.
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized … Ended

2023-509092-16-00 Phase II 1 country Akershus University Hospital

Showing 1–15 of 15 trials

← All drugs A–Z